ClinicalTrials.gg
Not yet recruitingNCT07904819RAPIDUpdated Oct 29, 2026

Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma

A Phase 2 interventional study of Anlotinib Hydrochloride Capsules and Benmelstobart in Nasopharyngeal Cancinoma (NPC), sponsored by Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
214
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation based on post-induction plasma cell-free Epstein-Barr virus DNA (cfEBV DNA) status and radiographic response in patients with locoregionally advanced nasopharyngeal carcinoma. All participants will receive three cycles of induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart. After induction therapy, participants with cfEBV DNA clearance and a complete or partial response will be classified as low risk and receive intensity-modulated radiotherapy alone, followed by adjuvant Benmelstobart. Participants without cfEBV DNA clearance or with stable or progressive disease will be classified as high risk and receive intensity-modulated radiotherapy with concurrent cisplatin, followed by adjuvant Benmelstobart and capecitabine. The primary objectives are to evaluate the post-induction therapy complete response rate in the overall study population and event-free survival in the high-risk group.

Read the detailed description

This is a multicenter, prospective study evaluating a biomarker- and response-guided risk-adapted treatment strategy for locoregionally advanced nasopharyngeal carcinoma. All participants will receive three cycles of induction therapy (Gemcitabine + Cisplatin) with Anlotinib, a multi-targeting tyrosine kinase inhibitor, plus the PD-L1 inhibitor Benmelstobart. Risk assignment will be performed after completion of induction therapy using both plasma cell-free Epstein-Barr virus DNA (cfEBV DNA) status and radiographic tumor response. Participants with undetectable cfEBV DNA and a complete or partial response after induction therapy will be assigned to the low-risk group. These participants will then receive intensity-modulated radiotherapy without concurrent cisplatin, followed by adjuvant Benmelstobart. Participants with detectable cfEBV DNA after induction therapy, or whose best radiographic response is stable or progressive disease, will be assigned to the high-risk group. These participants will receive intensity-modulated radiotherapy with concurrent cisplatin, followed by adjuvant Benmelstobart and capecitabine. The study has two primary objectives: to evaluate the complete response rate after induction therapy in the overall study population and to evaluate event-free survival in the higher-risk group. Secondary evaluations include overall survival, distant metastasis-free survival, locoregional recurrence-free survival, cfEBV DNA clearance after induction therapy, safety, tolerability, and patient-reported quality of life.Exploratory analyses will investigate potential prognostic and treatment-response biomarkers in tumor tissue, blood, and stool samples. Clinical outcomes will also be explored across subgroups defined by age, sex, baseline cfEBV DNA level, percentage reduction or clearance of cfEBV DNA, clinical stage, and other relevant prognostic factors.

02

Conditions studied

  • Nasopharyngeal Cancinoma (NPC)

Keywords

  • anlotinib hydrochloride
  • PD-L1 antibody
  • Risk-Adapted therapy
  • chemoradiotherapy
03

In context

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,692 studies on the registry; 620 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤65 years at diagnosis, regardless of sex.
  2. Previously untreated nasopharyngeal carcinoma confirmed as non-keratinizing carcinoma according to the World Health Organization (WHO) classification.
  3. Locoregionally advanced nasopharyngeal carcinoma classified as stage II or III, excluding T3N0-1 disease, according to the 9th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) clinical staging system.
  4. performance score of 0-1.
  5. Adequate marrow function: white blood cell count > 4 × 10⁹/L >90g/L and count >100×10⁹/L
  6. Adequate hepatic and renal function:

    • Total ≤ 1.5 × (ULN)
    • (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN
    • Alkaline phosphatase ≤ 2.5 × ULN
    • clearance rate ≥ 60 ml/min
  7. Other laboratory and clinical criteria

    • Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and (ECG)
    • For patients aged >50 years with a history of smoking, normal pulmonary function test (PFT) results are required
    • For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits
  8. Patients must be informed of the nature of this study and give written , and be willing and able to comply with the study schedule, including follow-up visits, treatment procedures, laboratory testing, and other protocol-related requirements.
  9. Women of (WOCBP) must be willing to adhere to effective during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).
  10. Positive plasma Epstein-Barr virus (EBV) DNA before initiation of treatment (> 0 copies/mL).

Exclusion criteria

Exclusion Criteria:

  1. Positive for surface antigen (HBsAg) with hepatitis B virus DNA >1×10\^3 copies/mL, positive for anti- virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody
  2. Positive for anti- antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).
  3. Active pulmonary tuberculosis: Patients with a history of active tuberculosis within the past year should be excluded regardless of treatment status. Patients with a history of active pulmonary tuberculosis more than one year prior should also be excluded, unless they received confirmed and regular anti-tuberculosis treatment.
  4. Active, known, or suspected diseases, including but not limited to uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilators. Type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed.
  5. History of interstitial lung disease or pneumonia requiring oral or intravenous within the past year; use of vancomycin within the past month.
  6. Ongoing chronic systemic corticosteroid therapy (equivalent to or greater than prednisone >10mg per day) or any other therapy. Patients received inhale or topical corticosteroid are allowed.
  7. Uncontrolled cardiac conditions, such as:

    • Heart failure with (NYHA) classification ≥ Class II;
    • Unstable angina;
    • History of myocardial infarction within the past year;
    • Supraventricular or ventricular arrhythmias requiring treatment or intervention
  8. Pregnant or breastfeeding women (pregnancy testing should be considered for women of with active sexual life)
  9. History or presence of other , except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.
  10. Known to macromolecule protein products or any component of benmelstobart.
  11. Active infections requiring systemic treatment within 1 week prior to enrollment.
  12. Administration of within 30 days prior to the first dose of anlotinib hydrochloride.
  13. History of organ transplantation or hematopoietic stem cell transplantation.
  14. Presence of bleeding symptoms or a definite hemorrhagic tendency; specifically, cases with a high risk of bleeding from local recurrence, or those within one year post-radiotherapy assessed to have a high risk of necrosis, must be excluded.
  15. History of hypertension that remains poorly controlled with medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).
  16. Urinalysis showing urine protein ≥ ++, confirmed by 24-hour urine protein quantification ≥1.0 g.
  17. Factors significantly affecting the absorption of oral drugs, such as inability to swallow, chronic diarrhea, or intestinal obstruction.
  18. Any other condition assessed by the investigator as potentially compromising patient safety or compliance, such as severe illnesses requiring urgent treatment (including psychiatric disorders), significantly abnormal laboratory values, or other psychological, familial, or social risk factors.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    Low-Risk Group

    Participants with undetectable plasma cfEBV DNA and a radiographic complete response or partial response after three cycles of induction therapy \[Gemcitabine, 1g/m², intravenous infusion, Day 1 \& 8 + Cisplatin, 80mg/m², intravenous infusion, Day 1 + Anlotinib 10 mg, oral administration, Day 1-14 + Benmelstobart 1200 mg, intravenous infusion, Day 1; 3 cycles, Q3W \] are classified as low risk and receive the following treatment: Radiotherapy Alone: Intensity-modulated radiotherapy (IMRT), 70 Gy in 33 fractions, once daily, 5 days per week; Adjuvant Immunotherapy (5 cycles, Q3W): Benmelstobart 1200 mg, intravenous infusion, Day 1.

    Drug: Anlotinib Hydrochloride Capsules · Drug: Benmelstobart · Drug: Gemcitabine (GEM) · Radiation: Intensity-Modulated Radiotherapy · Drug: Cisplatin (80 mg/m2)

  • Experimental
    High-Risk Group

    Participants with detectable plasma cfEBV DNA or a radiographic response of stable disease or progressive disease after three cycles of induction therapy \[Gemcitabine, 1g/m², intravenous infusion, Day 1 \& 8 + Cisplatin, 80mg/m², intravenous infusion, Day 1 + Anlotinib 10 mg, oral administration, Day 1-14 + Benmelstobart 1200 mg, intravenous infusion, Day 1; 3 cycles, Q3W \] are classified as high risk and receive the following treatment: Concurrent Chemoradiotherapy (CCRT): IMRT, 70 Gy in 33 fractions, once daily, 5 days per week + Cisplatin 100 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W); Adjuvant Therapy: Benmelstobart 1200 mg, intravenous infusion, Day 1 (5 cycles, Q3W) + Capecitabine 650 mg/m², orally twice daily, Days 1-21 (17 cycles, Q3W).

    Drug: Anlotinib Hydrochloride Capsules · Drug: Benmelstobart · Drug: Gemcitabine (GEM) · Drug: Cisplatin (100mg/m2) · Radiation: Intensity-Modulated Radiotherapy · Drug: Capecitabine · Drug: Cisplatin (80 mg/m2)

Interventions

  • Induction Therapy: Anlotinib hydrochloride 10mg, oral administration, Day1-14, (3 cycles, Q3W)

  • Induction Therapy: Benmelstobart 1200 mg, intravenous infusion, Day 1 (3 cycles, Q3W); Adjuvant Therapy: Benmelstobart 1200 mg, intravenous infusion, Day 1 (5 cycles, Q3W)

  • Induction Therapy: Gemcitabine 1g/m2, intravenous infusion, Day 1\&8 (3 cycles, Q3W)

  • DrugCisplatin (100mg/m2)

    Drug page: Cisplatin

    Concurrent Chemoradiotherapy: Cisplatin 100 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W)

  • RadiationIntensity-Modulated Radiotherapy

    70 Gy in 33 fractions, once daily, 5 days per week

  • Adjuvant Therapy: Capecitabine 650 mg/m², orally twice daily, Days 1-21 (17 cycles, Q3W)

  • DrugCisplatin (80 mg/m2)

    Drug page: Cisplatin

    Induction Therapy: Cisplatin 80 mg/m², intravenous infusion, Day 1 (2 cycles, Q3W);

06

What researchers measure

Primary outcomes

  1. Post-induction Therapy Complete Response Rate (post-IT CRR)

    The proportion of patients achieving complete response following induction therapy

    Time frame: Within 9 to 21 days after the last dose of induction therapy

  2. Event-Free Survival (EFS) in the High-Risk Group

    The time from the date of enrollment to the first occurrence of locoregional recurrence, distant metastasis, or death from any cause.

    Time frame: 3 years & 5 years

Secondary outcomes

  1. Overall survival (OS)

    From date of enrollment to date of death from any cause

    Time frame: 3 years & 5 years

  2. Distant Metastasis-Free Survival (DMFS)

    From the date of enrollment to the date of first documented distant metastasis or death from any cause, whichever occurs first.

    Time frame: 3 years & 5 years

  3. Locoregional Recurrence-Free Survival (LRRFS)

    From the date of enrollment to the date of first documented locoregional recurrence or death from any cause, whichever occurs first.

    Time frame: 3 years & 5 years

  4. Adverse Events (AEs)

    Graded according to CTCAE V5.0

    Time frame: 3 years & 5 years

  5. Patient-Reported Adverse Events (PRO-CTCAE)

    Patient-reported adverse events will be assessed using selected items from the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE™), Chinese version, administered at each treatment cycle. Patients will self-report and rate the severity of relevant adverse events throughout the study treatment period.

    Time frame: At the end of each treatment cycle (each cycle is 21 days), from Cycle 1 of induction therapy through Cycle 5 of adjuvant therapy

  6. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score

    Assesses general quality of life in cancer patients. Items are scored and linearly transformed to a 0-100 scale. For functional scales, higher scores indicate better functioning; for symptom scales, higher scores indicate greater symptom burden.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

  7. EORTC Quality of Life Questionnaire Head and Neck 35 (EORTC QLQ-H&N35, version 1)

    Assesses head and neck cancer-specific symptoms. Items are scored and linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

  8. Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N, Chinese version 4)

    Assesses quality of life specific to head and neck cancer patients. Items are rated on a 0-4 scale and summed to a total score of 0-156. Higher scores indicate better quality of life.

    Time frame: At baseline, after completion of induction therapy (Week 10), at the end of IMRT (Week 16), at the last adjuvant cycle (Week 31; each cycle is 21 days), and at 1, 3, 12, 24, 36, 48, and 60 months post-radiotherapy

Other outcomes

  1. Correlation of Tumor, Peripheral Blood, and Fecal Biomarkers with Treatment Efficacy and Patient Prognosis

    Tumor tissue biomarkers: PD-L1 expression level, tumor-infiltrating lymphocyte (TIL) density, immune score, expression profiles of immune checkpoint molecules and immune cell subpopulations, and tumor cell transcriptomic gene expression; Peripheral blood biomarkers: Immune cell populations, immune repertoire, and cytokine profiles; Fecal biomarkers: Composition and characteristics of fecal biomarkers in relation to treatment response and prognosis

    Time frame: 3 years & 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2026
First posted
Oct 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2033
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07904819
Responsible party
Jun Ma, MD (Professor, Sun Yat-sen University) — Principal investigator
First posted
Oct 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

Jun Ma, M.D.
Contact
majun2@mail.sysu.edu.cn
+862087343469
Ya-Qin Wang, Ph.D.
Contact
wangyaq@sysucc.org.cn
+862087343029

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catequentinib hydrochloride

Start the discussion